You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
羅欣藥業(002793.SZ): 子公司鹽酸納美芬注射液獲批上市
格隆匯 10-21 16:15

格隆匯10月21日丨羅欣藥業(002793.SZ)宣佈,公司下屬子公司山東羅欣藥業集團股份有限公司於近日收到國家藥品監督管理局核准簽發的鹽酸納美芬注射液《藥品註冊證書》。

納美芬為阿片拮抗劑,是納曲酮的6-亞甲基類似物。鹽酸納美芬注射液用於完全或部分逆轉阿片類藥物的作用,包括由天然的或合成的阿片類藥物引起的呼吸抑制。

鹽酸納美芬注射液由Baxte rHealthcare Corporation開發,於1995年4月被美國食品藥品管理局(FDA)批准上市,商品名為REVEX,規格分別為:1ml:0.1mg和1ml:1mg,原研未在國內上市。

根據IQVIA數據,2020年度鹽酸納美芬注射液的全球規模為1.34億美元(以出廠價計算);國內市場規模為12.92億人民幣(以招標價計算)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account